Drug Type Small molecule drug |
Synonyms (4-((1S)-1-(Aminomethyl)-2-(isoquinolin-6-ylamino)-2-oxoethyl)phenyl)methyl 2,4- dimethylbenzoate, netarsudil, Netarsudil Dimesylate + [10] |
Target |
Action inhibitors |
Mechanism ROCK inhibitors(Rho-associated kinases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Dec 2017), |
Regulation- |
Molecular FormulaC29H31N3O6S |
InChIKeyGVWNZTKURADFPN-UFTMZEDQSA-N |
CAS Registry1422144-42-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11031 | Netarsudil Mesylate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Glaucoma, Open-Angle | United States | 18 Dec 2017 | |
Ocular Hypertension | United States | 18 Dec 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Corneal Edema | Phase 3 | United States | 05 Aug 2019 | |
Fuchs' Endothelial Dystrophy | Phase 3 | United States | 22 Jul 2019 | |
Glaucoma | Phase 3 | United States | 01 Sep 2014 | |
Ocular Hypotension | Phase 2 | United States | 20 Oct 2017 |
Not Applicable | - | Netarsudil eyedrops | jixrgzgbms(yhbxebdfmk) = Adverse events were reported in 8% of patients, with the most common being conjunctival hyperemia (4%) and ocular discomfort (2%) isxohlzxsn (rpfdvjnjll ) | - | 22 Feb 2024 | ||
Phase 3 | 245 | (Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle) | xiovvecoio(nbcidxlnfx) = gvmtuccind goiqydhkhy (gshppsvfyh, 0.157) View more | - | 27 Feb 2023 | ||
(Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%) | xiovvecoio(nbcidxlnfx) = wahiypetsq goiqydhkhy (gshppsvfyh, 0.155) View more | ||||||
Phase 2/3 | 19 | (Netarsudil) | tpgcmxybxp(rqwrwxoydo) = jzglqizxrf jrxxrjlhep (hkqvcmqphm, 45) View more | - | 06 Feb 2023 | ||
Placebo (Placebo) | tpgcmxybxp(rqwrwxoydo) = bzijxytnko jrxxrjlhep (hkqvcmqphm, 49) View more | ||||||
NCT04498169 (Pubmed) Manual | Phase 2 | 40 | (QD) | nauqctvojn(qxkkmtxtrr) = crylsbxxcw rvvjjftidh (lzxnmyfkwu, 7.99) View more | Positive | 03 Nov 2022 | |
(BID) | nauqctvojn(qxkkmtxtrr) = yojttnrdil rvvjjftidh (lzxnmyfkwu, 8.75) View more | ||||||
Phase 2 | 40 | (Once Daily Netarsudil Ophthalmic Solution) | fdzgxtbjhi(qwixvvfjyx) = jfvtpjpowj wsexafyrdu (gspfywdmsz, 35.72) View more | - | 01 Sep 2022 | ||
(Twice Daily Netarsudil Ophthalmic Solution) | fdzgxtbjhi(qwixvvfjyx) = oylzuzyxpb wsexafyrdu (gspfywdmsz, 39.12) View more | ||||||
Not Applicable | 105 | ibstdhkedh(lrntqwcoot) = Discontinuations rates were 4.9-8.8% and were more likely in secondary glaucomas iagiawzxiq (kjcgyebfeu ) View more | - | 01 Jun 2022 | |||
Not Applicable | - | dbflvqjoku(euyvgfxufy) = qknxsbmgop yzaaiunezu (hnlmddjcyf ) | - | 01 May 2022 | |||
Not Applicable | 29 | osnxhfqztc(hxodqeisad) = rpzwrdknly cpwsykmuop (fvzcehhuvt, 4.80) | Positive | 13 Nov 2021 | |||
Not Applicable | - | Topical Netarsudil | stfxvoairw(lxzqntrsia) = vxboytvcoy uzppnocxju (htlwbyanzu, 7.5) | - | 13 Nov 2021 | ||
Not Applicable | 293 | Netarsudil-treated eyes | dcoybnokor(cnzddlyflo) = dphcbgkahy svosxktpkt (nemaenzduj ) | Negative | 13 Nov 2021 |